Journal of Thrombosis and Thrombolysis

Papers
(The TQCC of Journal of Thrombosis and Thrombolysis is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database49
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity45
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection45
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery34
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia34
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team29
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry28
Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment28
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors24
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians24
Management of bone marrow biopsy related bleeding risks: a retrospective observational study24
Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status23
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate22
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia21
Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic20
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer19
Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA18
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone17
Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals17
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series17
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy17
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy16
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients16
Potent platelet inhibition with peri-procedural tirofiban may attenuate progression of atherosclerosis in patients with acute coronary syndromes16
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding16
Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review15
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality14
Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection14
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes14
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison14
Evaluation of coagulation status using clot waveform analysis in general ward patients with COVID-1914
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum13
Thrombosis in VEXAS syndrome13
Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies13
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome13
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri13
Effectiveness and safety of the direct oral anticoagulants in non-triple positive antiphospholipid syndrome without prior arterial thromboembolism13
Forensic autopsy-confirmed thrombosis-related deaths: the danger in the bones12
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis12
Venous and arterial thromboembolic disease in COVID-1912
Popliteal cysts are not a risk factor for lower extremity deep vein thrombosis12
Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes12
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy11
Thrombotic superior vena cava syndrome: a national emergency department database study11
The clot thickens—enhanced integration of stroke and thrombosis training11
Metformin therapy in COVID-19: inhibition of NETosis11
Endothelial progenitor cells overexpressing platelet derived growth factor-D facilitate deep vein thrombosis resolution11
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study11
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction11
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid10
Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall10
Atypical late diagnosis of Noonan syndrome revealed by bleedings due to platelet dysfunction10
Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event10
Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation10
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study9
U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients9
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia9
A comprehensive review of vascular complications in COVID-199
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature9
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients9
Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry)9
Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves9
Vitamin D levels and C-reactive protein/albumin ratio in pregnant women with cerebral venous sinus thrombosis9
Management of tandem occlusions in patients who receive rtPA9
Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-199
0.11566686630249